Abstract
Goals of work
We set out to assess the preference of patients with common cancers involving bone receiving intravenous bisphosphonate therapy for either pamidronate (P) or zoledronic acid (Z) and their preference for the location of the infusion (clinic or home). We also aimed to monitor these patients’ renal safety, and to compare their time in clinic to receive P and Z infusions.
Patients and methods
Enrolled in the study were 184 patients, and all received initial infusions of Z (so any first infusion reactions did not confound preferences for P). For their second and third infusions, patients were randomized to receive Z then P or P then Z, and questioned on their preferences. For up to 1 year they continued on Z infusions every 3–4 weeks, while their renal safety was monitored. Where practical, later infusions were given at home (rather than in the clinic) and patients questioned on their preferred infusion location. In a convenience subset of 43 patients, clinic use for Z and P infusions was also measured by timing infusions and other procedures.
Main results
Of 144 patients who received a third infusion, 138 responded to questions on bisphosphonate preference, and of these 138, 92% (127) preferred Z to P, because shorter infusions caused less disruption to their day. Only 12% of eligible patients (16/138) received home infusions, but 13/14 questioned preferred this location. Among 184 patients, 19 episodes of renal impairment were noted, mostly owing to disease progression (e.g. obstructive uropathy), with none linked to Z therapy. The mean clinic time taken to receive Z and any concomitant therapy was about half that for P (78 vs 161 min).
Conclusions
Cancer patients prefer shorter bisphosphonate infusions—and at home, where practical. Regular Z 4 mg infusions appear to be safe in these patients, with routine monitoring of serum creatinine. Using Z rather than P could save busy cancer centres time and improve patient satisfaction.
Similar content being viewed by others
References
Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey JA, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y (2001) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase II, double-blind, comparative trial. Cancer J 7:377–387
Rosen L, Harland SJ, Oosterlinck W (2002) Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am J Clin Oncol 25 [6 Suppl 1]:S19–24
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B; Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Caner Inst 94:1458–1468
Pecherstorfer M, Jilch R, Sauty A, Horn E, Keck AV, Zimmer-Roth I, Thiebaud D (2000) Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J Bone Miner Res 15:147–154
Wardley A, Davidson N, Barrett-Lee P, Hong A, Mansi J, Dodwell D, Murphy R, Mason T, Cameron D (2003) Zometa(r) (zoledronic acid) significantly improves pain scores in patients with skeletal metastases secondary to breast cancer—analysis of home versus hospital administration. Proc Am Soc Clin Oncol, abstract no. 3012
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was sponsored by Novartis Pharmaceuticals (Australia) Pty. Ltd.
The findings were presented in part at the 2003 Meeting of the American Society of Clinical Oncology.
Rights and permissions
About this article
Cite this article
Chern, B., Joseph, D., Joshua, D. et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer 12, 463–466 (2004). https://doi.org/10.1007/s00520-004-0628-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0628-z